Press Releases
U.S. FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Medicine ACE910 for People With Hemophilia A With Factor VIII Inhibitors
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of hemophilia A Ninth breakthrough therapy designation for Genentech’s portfolio of medicines...
News
Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015 Results Presented for the First Time at...
News
Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program
Data in Nine Difficult-to-Treat Cancers from Merck’s KEYTRUDA® (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New...
News
New pre-clinical data shows Alcon’s pre-loaded IOL delivery system creates low corneal incision enlargement and preserves final incision size in patients
Data presented at ESCRS shows UltraSert™ Pre-loaded IOL Delivery System created the least corneal incision enlargement and the lowest final incision size versus two...
Industry Reports
CTI BioPharma Announces $15.7 Million Registered Direct Offering
CTI BioPharma Corp. announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock...
Clinical Trials
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO
Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. announced that the U.S. Food and Drug Administration (FDA) has accepted...
Press Releases
New Directions in Breast Conserving Surgery – An Interview with Pat Whitworth, MD and Frank Vicini, MD
Additionally, Frank Vicini, MD, Chief Academic Officer for Michigan Healthcare Professionals and 21st Century Oncology and Professor of Radiation Oncology, discusses data from...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read